Diet Stimulation as a Synergistic Factor of Aggravation in a Pancreatic Bile Duct Ligation-Induced Rat Pancreatitis Model
スポンサーリンク
概要
- 論文の詳細を見る
We evaluated the association between aggravation of pancreatitis and multiple factors enhancing pancreatic exocrine secretion using a rat model of pancreatic bile duct ligation (PBDL)-induced pancreatitis. Under fasting and non-fasting conditions, a PBDL group, a second group treated by hepatic bile duct ligation (BDL) and a third group treated by pancreatic duct ligation (PDL) were compared in terms of serum amylase (S-amylase) activity. The S-amylase activity in the PBDL group was higher than in the sham group. In the PDL group, the increase in S-amylase activity was lower than in the PBDL group. In the BDL group, no increase in S-amylase activity was observed. Diversion of pancreatic and/or bile juice in these groups resulted in no increase of S-amylase activity. Truncal vagotomy or injection of an anticholinergic drug or a cholecystokinin (CCK)_1-receptor antagonist inhibited pancreatic exocrine secretion and S-amylase activity in the non-fasting PBDL group but not in the fasting PBDL group. These results suggest that retention of pancreatic juice in the pancreatic duct is necessary for the increase of S-amylase activity, and that dietary stimulation and impaired duodenal inflow of bile and pancreatic juice commonly enhance pancreatic exocrine secretion, acting synergistically as aggravating factors in pancreatitis. CCK and the vagus nerve system appears to be involved in enhancing pancreatic exocrine secretion with diet stimulation as an aggravating factor.
- 公益社団法人日本薬学会の論文
- 2000-11-01
著者
-
Yoshinaga Koji
Central Research Laboratories, Zeria Pharmaceutical Co., Ltd.
-
Yoshinaga Koji
Central Res. Laboratories Zeria Pharmaceutical Co. Ltd.
-
Yoshinaga Koji
Central Research Laboratories Zeria Pharmaceutical Co. Ltd
-
SEGAWA Yoshihide
Department of Pharmacology, Central Research Laboratories, Zeria Pharmaceutical Co., Ltd.,
-
SEGAWA Yoshihide
Zeria Pharmaceutical Co., Ltd.
-
Segawa Y
Zeria Pharmaceutical Co. Ltd.
-
Segawa Yoshihide
Department Of Pharmacology Central Research Laboratories Zeria Pharmaceutical Co. Ltd.
-
WASHIZUKA Masataka
Central Research Laboratories, Zeria Pharmaceutical Co., Ltd
-
YOSHINAGA Koji
Department of Applied Research, Central Research Laboratories, Zeria Pharmaceutical Co., Ltd.,
-
WASHIZUKA Masataka
Department of Applied Research, Central Research Laboratories, Zeria Pharmaceutical Co., Ltd.,
-
Washizuka Masataka
Central Research Laboratories Zeria Pharmaceutical Co. Ltd
関連論文
- Pharmacological Evaluation of Analgesic Effects of the Cholecystokinin2 Receptor Antagonist Z-360 in Mouse Models of Formalin- and Cancer-Induced Pain
- Z-100, an Immunomodulatory Arabinomannan Extracted from Mycobacterium tuberculosis Strain Aoyama B, Augments Anti-tumor Activities of X-Ray Irradiation against B16 Melanoma in Association with the Improvement of Type 1T Cell Responses(Miscellaneous)
- Antimetastatic Effect of an Immunomodulatory Arabinomannan Extracted from Mycobacterium tuberculosis Strain Aoyama B, Z-100, through the Production of Interleukin-12(Miscellaneous)
- Anti-Tumor Mechanism of Z-100, an Immunomodulatory Arabinomannan Extracted from Mycobacterium tuberculosis Strain Aoyama B, on Pulmonary Metastases of B16F10 Melanoma : Restoration of Helper T Cell Responses via Suppression of Glucocorticoid-Genesis
- Z-360, a Novel Cholecystokinin-2/Gastrin Receptor Antagonist, Inhibits Gemcitabine-Induced Expression of the Vascular Endothelial Growth Factor Gene in Human Pancreatic Cancer Cells
- Z-100,Extracted from Mycobacterium tuberculosis Strain Aoyama B, Inhibits the Development of Collagen-Induced Arthritis in Mice
- Possible Changes in Expression of Chemotaxin LECT2 mRNA in Mouse Liver after Concanavalin A-Induced Hepatic Injury
- D-Galactosamine-Induced Mouse Hepatic Apoptosis : Possible Involvement with Tumor Necrosis Factor, but not with Caspase-3-Activity
- Fasting Exacerbates Acute Pancreatitis by Occlusion of the Common Bile Duct in Rats
- Diet Stimulation as a Synergistic Factor of Aggravation in a Pancreatic Bile Duct Ligation-Induced Rat Pancreatitis Model
- Cholecystokinin Acts as an Essential Factor in the Exacerbation of Pancreatic Bile Duct Ligation-Induced Rat Pancreatitis Model Under Non-fasting Condition
- Antiallergic Effect of ZCR-2060: Antihistaminic Action.
- Antiallergic Effects of ZCR-2060: Effect on Allergic Cutaneous Reactions and Rhinitis Models in Mice and Rats.